276 related articles for article (PubMed ID: 23146022)
21. Avidin fusion protein-expressing lentiviral vector for targeted drug delivery.
Lesch HP; Pikkarainen JT; Kaikkonen MU; Taavitsainen M; Samaranayake H; Lehtolainen-Dalkilic P; Vuorio T; Määttä AM; Wirth T; Airenne KJ; Ylä-Herttuala S
Hum Gene Ther; 2009 Aug; 20(8):871-82. PubMed ID: 19419273
[TBL] [Abstract][Full Text] [Related]
22. Avidin-biotin technology in targeted therapy.
Lesch HP; Kaikkonen MU; Pikkarainen JT; Ylä-Herttuala S
Expert Opin Drug Deliv; 2010 May; 7(5):551-64. PubMed ID: 20233034
[TBL] [Abstract][Full Text] [Related]
23. Synergistic gene and drug tumor therapy using a chimeric peptide.
Han K; Chen S; Chen WH; Lei Q; Liu Y; Zhuo RX; Zhang XZ
Biomaterials; 2013 Jun; 34(19):4680-9. PubMed ID: 23537665
[TBL] [Abstract][Full Text] [Related]
24. Mimicking the biological ligand-receptor principle for universal target gene delivery mediated by avidin-biotin interaction.
Qu W; Ren S; Kuang Y; Jiang XJ; Zhuo RX; Zhang XZ
Adv Healthc Mater; 2013 Mar; 2(3):418-21. PubMed ID: 23184873
[TBL] [Abstract][Full Text] [Related]
25. Stearylated antimicrobial peptide [D]-K6L9 with cell penetrating property for efficient gene transfer.
Zhang W; Song J; Liang R; Zheng X; Chen J; Li G; Zhang B; Wang K; Yan X; Wang R
Peptides; 2013 Aug; 46():33-9. PubMed ID: 23727033
[TBL] [Abstract][Full Text] [Related]
26. Enhanced gene delivery by avidin-displaying baculovirus.
Räty JK; Airenne KJ; Marttila AT; Marjomäki V; Hytönen VP; Lehtolainen P; Laitinen OH; Mähönen AJ; Kulomaa MS; Ylä-Herttuala S
Mol Ther; 2004 Feb; 9(2):282-91. PubMed ID: 14759812
[TBL] [Abstract][Full Text] [Related]
27. Biotin-triggered release of poly(ethylene glycol)-avidin from biotinylated polyethylenimine enhances in vitro gene expression.
Xiong MP; Forrest ML; Karls AL; Kwon GS
Bioconjug Chem; 2007; 18(3):746-53. PubMed ID: 17375897
[TBL] [Abstract][Full Text] [Related]
28. A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene.
Yu W; Pirollo KF; Rait A; Yu B; Xiang LM; Huang WQ; Zhou Q; Ertem G; Chang EH
Gene Ther; 2004 Oct; 11(19):1434-40. PubMed ID: 15229629
[TBL] [Abstract][Full Text] [Related]
29. Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification.
Parrott MB; Adams KE; Mercier GT; Mok H; Campos SK; Barry MA
Mol Ther; 2003 Oct; 8(4):688-700. PubMed ID: 14529842
[TBL] [Abstract][Full Text] [Related]
30. Biotinylated disulfide containing PEI/avidin bioconjugate shows specific enhanced transfection efficiency in HepG2 cells.
Zeng X; Sun YX; Zhang XZ; Zhuo RX
Org Biomol Chem; 2009 Oct; 7(20):4201-10. PubMed ID: 19795058
[TBL] [Abstract][Full Text] [Related]
31. A multifunctional PEI-based cationic polyplex for enhanced systemic p53-mediated gene therapy.
Moffatt S; Wiehle S; Cristiano RJ
Gene Ther; 2006 Nov; 13(21):1512-23. PubMed ID: 16763664
[TBL] [Abstract][Full Text] [Related]
32. Development of a novel histone H1-based recombinant fusion peptide for targeted non-viral gene delivery.
Soltani F; Sankian M; Hatefi A; Ramezani M
Int J Pharm; 2013 Jan; 441(1-2):307-15. PubMed ID: 23200954
[TBL] [Abstract][Full Text] [Related]
33. Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting.
Campos SK; Barry MA
Virology; 2006 Jun; 349(2):453-62. PubMed ID: 16504233
[TBL] [Abstract][Full Text] [Related]
34. Mesenchymal stem cells as a novel carrier for targeted delivery of gene in cancer therapy based on nonviral transfection.
Hu YL; Huang B; Zhang TY; Miao PH; Tang GP; Tabata Y; Gao JQ
Mol Pharm; 2012 Sep; 9(9):2698-709. PubMed ID: 22862421
[TBL] [Abstract][Full Text] [Related]
35. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery.
Asai T; Trinh R; Ng PP; Penichet ML; Wims LA; Morrison SL
Biomol Eng; 2005 Feb; 21(6):145-55. PubMed ID: 15748688
[TBL] [Abstract][Full Text] [Related]
36. A facile preparation of novel multifunctional vectors by non-covalent bonds for co-delivery of doxorubicin and gene.
Ma M; Yuan ZF; Chen XJ; Li F; Zhuo RX
Acta Biomater; 2012 Feb; 8(2):599-607. PubMed ID: 22100345
[TBL] [Abstract][Full Text] [Related]
37. Peptide-based glioma-targeted drug delivery vector gHoPe2.
Eriste E; Kurrikoff K; Suhorutšenko J; Oskolkov N; Copolovici DM; Jones S; Laakkonen P; Howl J; Langel Ü
Bioconjug Chem; 2013 Mar; 24(3):305-13. PubMed ID: 23350661
[TBL] [Abstract][Full Text] [Related]
38. Influential factors associated with biotinylated disulfide containing PEI/avidin bioconjugate mediated gene delivery in HepG2 cells.
Zeng X; Sun YX; Zhang XZ; Zhuo RX
Mol Biosyst; 2010 Oct; 6(10):1933-40. PubMed ID: 20603675
[TBL] [Abstract][Full Text] [Related]
39. In vitro targeting of avidin-expressing glioma cells with biotinylated persistent luminescence nanoparticles.
Maldiney T; Kaikkonen MU; Seguin J; le Masne de Chermont Q; Bessodes M; Airenne KJ; Ylä-Herttuala S; Scherman D; Richard C
Bioconjug Chem; 2012 Mar; 23(3):472-8. PubMed ID: 22250884
[TBL] [Abstract][Full Text] [Related]
40. Improvement of peptide vectors for gene delivery with active targeting profiles for phosphatidylserine.
Kuriyama S; Taguchi Y; Nishimura K; Yanagibashi K; Katayama Y; Niidoime T
J Pept Sci; 2009 Feb; 15(2):114-9. PubMed ID: 19090508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
